News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CEL-SCI (CVM) Receives Key Japanese Patent for Its Investigational Phase III Cancer Therapy Multikine


11/28/2012 9:28:56 AM

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Japanese patent office has issued a key patent covering CEL-SCI’s investigational cancer drug, Multikine (Leukocyte Interleukin, Injection)*. The patent, Japanese patent number 5,122,279, is titled, “A Method of Pre-Sensitizing Cancer Prior to Treatment with Radiation and/or Chemotherapy and a Novel Cytokine Mixture”. Key patents on Multikine have now been issued in the largest pharmaceutical markets in the world: the United States, European Union, China and Japan.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES